Skip to main content
. 2017 Jun;102(6):1054–1065. doi: 10.3324/haematol.2016.159053

Figure 5.

Figure 5.

Primary human ALDH1A1− acute myeloid leukemias (AMLs) are sensitive to 4HC+ATO while ALDH1A1+ AMLs are relatively resistant. (A) In vitro sensitivity of primary human AMLs to 4HC and ATO. Primary human AMLs were treated overnight with 4HC+ATO (12.5 μM+2 μM) and DNA damage and cell viability were measured (4 AMLs in triplicate; ***P<0.0005). (B) Sensitivity of Aldefluor+ and Aldefluor− fractions from 2 representative AMLs purified by FACS and then treated overnight with 4HC+ATO (12.5 μM+2 μM) (n=6; **P<0.005, ***P<0.0005). (C) DNA damage (γH2AX) of Aldefluor+ and Aldefluor− fractions from an ALDH1A1+ AML following overnight treatment with 4HC+ATO (n=3; **P<0.005, ***P<0.0005). (D) Relative sensitivity of Aldefluor+ fraction from an ALDH1A1+ AML to 4HC+ATO with and without 5 μM DEAB at 18 hours (n=3; *P<0.05). (A–D) Bars represent mean±SD. (C–D) Results of technical triplicates are shown.